Tenax Therapeutics Inc. (TENX)
NASDAQ: TENX
· Real-Time Price · USD
7.50
-0.11 (-1.45%)
At close: Oct 03, 2025, 3:59 PM
7.50
0.00%
After-hours: Oct 03, 2025, 04:10 PM EDT
-1.45% (1D)
| Bid | 7.42 |
| Market Cap | 34.22M |
| Revenue (ttm) | 2K |
| Net Income (ttm) | -31.48M |
| EPS (ttm) | 2.94 |
| PE Ratio (ttm) | 2.55 |
| Forward PE | -3.04 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 7.57 |
| Volume | 49,925 |
| Avg. Volume (20D) | 53,636 |
| Open | 7.75 |
| Previous Close | 7.61 |
| Day's Range | 7.39 - 7.91 |
| 52-Week Range | 3.25 - 7.91 |
| Beta | 1.58 |
| Ex-Dividend Date | n/a |
About TENX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TENX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TENX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts7 months ago
+3.15%
Tenax Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
11 months ago
+10.65%
Tenax Therapeutics shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a price target of $16.
5 months ago · seekingalpha.com
Tenax: Phase 3 Heart Failure Program Continues With 2 Key CatalystsTenax Therapeutics is advancing levosimendan in two phase 3 studies for PH-HFpEF, with LEVEL-2 starting in 2025 and topline data from LEVEL expected mid-2026. Levosimendan could be the first disease-m...